Date: October 19, 2026
Board Meeting Outcomes
Shareholders of Max Healthcare Institute Limited approved the following items through Postal Ballot by way of remote e-voting on October 19, 2026:
- Max Healthcare Institute Limited Performance Linked Restricted Stock Unit Scheme 2026 and grant of Performance Linked Restricted Stock Units to the Eligible Employees of the Company
- Grant of Performance Linked Restricted Stock Units under the 'Max Healthcare Institute Limited Performance Linked Restricted Stock Unit Scheme 2026' to the Eligible Employees of the Subsidiary Companies
- Alteration of the Main Objects Clause of the Memorandum of Association of the Company
Other Operational / Legal / Strategic Disclosures
Performance Linked Restricted Stock Unit Scheme 2026 Details
- The scheme complies with SEBI (SBEB) Regulations, 2021
- Total shares covered: 73,50,000 equity shares of face value ₹10/- each
- Represents approximately 0.76% of the paid-up equity share capital of the Company as on August 13, 2026
- Exercise Price: ₹10 per Equity Share (face value)
- Exercise Period: Commences on respective Vesting Date and expires upon completion of three years from the date of such Vesting
- No options have been granted under the Scheme as of the disclosure date
- Detailed terms available on Company's website at www.maxhealthcare.in/employee-benefit-scheme-documents
Memorandum of Association Alteration Details
The Main Objects Clause (Clause III. (A)) of the Memorandum of Association is being amended by inserting three new sub-clauses (7, 8, and 9) after existing sub-Clause 6, subject to approval of Registrar of Companies/Ministry of Corporate Affairs:
Sub-Clause 7: To establish, promote, develop, own, acquire, run, manage and operate medical colleges, medical institutions, teaching institutions and other educational institutions for imparting undergraduate, postgraduate, doctoral and other medical, healthcare and allied health education and training. This includes education and training in medicine, nursing, pharmacy, physiotherapy, rehabilitation, allied health sciences, healthcare administration, hospital management and other related disciplines. The company will establish teaching hospitals, clinical facilities, and undertake research and skill development in these fields, subject to applicable laws and approvals.
Sub-Clause 8: To manufacture, formulate, process, develop, produce, prepare, package, market, distribute, sell, purchase, import, export, supply and otherwise deal in pharmaceuticals, pharmaceutical preparations, formulations, medicines, drugs, medical preparations, enzymes, pharmaceutical intermediates, injectables, radiopharmaceuticals, radioisotopes and other medical healthcare products. This specifically includes Fluorodeoxyglucose (FDG) and other radiopharmaceuticals produced through cyclotron, proton and other particle accelerator facilities. The company will establish, acquire, install, operate and maintain cyclotron, proton and other particle accelerator facilities and related laboratories for manufacture, production, processing, research and development of such products.
Sub-Clause 9: To establish, operate, manage and provide food and beverage and allied services in connection with hospitals, medical colleges, medical institutions, healthcare facilities, educational institutions and other establishments of the Company. This includes cafeterias, canteens, food courts, catering facilities, restaurants, cafés, bakeries, confectioneries and other food and beverage establishments, including preparation, processing, manufacture, procurement, packaging, distribution, marketing, sale and supply of food, beverages and allied products.
KMP / Board / Auditor Changes
Not Specified
Dividend Declaration or Non-Declaration
Not Specified
Financial Results
Not Specified
Disinvestment / Strategic Actions
Not Specified